abs137.txt	background		angelman	syndrome	(as)	is	a	severe	neurodevelopmental	disorderlacking	effective	therapies	as	caused	by	mutations	in	ubiquitin	proteinligase	e3a	(ube3a)	which	genomically	imprinted	such	that	only	the	maternallyinherited	copy	expressed	neurons	we	previously	demonstrated	thattopoisomerase	i	(top1)	inhibitors	could	successfully	reactivate	dormantpaternal	allele	of	ube3a	mouse	model	also	previouslyshowed	one	top1	inhibitor	topotecan	unsilence	paternal	ininduced	pluripotent	stem	cell-derived	from	individuals	with	althoughtopotecan	has	been	well-studied	and	fda-approved	for	cancer	therapy	itslimited	cns	bioavailability	will	likely	restrict	therapeutic	use	topotecanin	goal	this	study	was	to	identify	additional	withsimilar	efficacy	expectation	these	be	tested	inthe	future	safety	assess	their	potential	astherapeutics	methods	13	indenoisoquinoline-derived	identifycompounds	primarycortical	were	isolated	embryonic	day	14	5	(e14	5)	mice	aube3a-yfp	fluorescent	tag	on	(ube3am+/pyfp	mice)	or	thatlack	maternal	hence	(ube3am-/p+	werecultured	7	days	treated	drug	72	h	examined	ube3aprotein	expression	western	blot	fluorescence	immunostaining	dose	responsesof	compounds	determined	across	log	range	treatments	andcytotoxicity	using	luciferase-based	assay	results	all	unsilenced	paternalube3a	several	exhibited	favorable	unsilencingproperties	similar	indotecan	(lmp400)	mosteffective	based	estimated	emax	(maximum	response	unsilencing	paternalube3a)	ec50	(half	maximal	concentration)	conclusions	provide	pharmacological	profiles	indenoisoquinoline-derivedtop1	unsilencers	wereeffective	at	although	variable	andpotency	better	profile	ofube3a	compared	our	previous	lead	compound	takentogether	its	structural	analogues	are	therapeuticswhose	translational	treatment	should	further	assessed
